NCT05169177Recruiting
Radio-opaque Contrast Agents for Liver Cancer Targeting With KIM During Radiation Therapy
Source: ClinicalTrials.gov · Last updated 19 May 2026
Brief summary (registry, in English)
This observational study will investigate the properties of image files standardly collected during radiation therapy treatment in a cross-section of liver cancer patients who received stereotactic ablative body radiation therapy (SABR) after trans-catheter arterial chemo emobilisation (TACE). Specifically, it will determine whether the radio-opaque contrast agents in the image files can be detected by tumour-tracking software (KIM).
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 50 (estimated)
- First submitted
- 8 Dec 2021
- Start date
- 17 Oct 2022
- Primary completion date
- 31 Oct 2026
- Lead sponsor
- University of Sydney
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT05169177
What you commit to
- Study type: Observational
- Planned participants: 50
- From 17 Oct 2022 to the primary completion date, 31 Oct 2026
- 5 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Age
- Less than 18 years of age
Other
- Minimum image dataset is not available
- Image dataset is not in a compatible format
Who the study is looking for
- Received or will receive stereotactic ablative body radiotherapy (SABR) treatment for liver cancer at a participating site.
- Received a radio-opaque contrast agent (e.g. Lipiodol™ or DC Bead LUMI™) that is visible on the radiation treatment planning CT scan
- The radio-opaque contrast agent mass is or will be within the x-ray imaging field of view during the CBCT scan and any planned intra-fraction imaging. Note that there is no requirement of the distance between the contrast agent mass and the treated tumour as the goal of the study is the contrast agent mass tracking.
- Provides written informed consent (prospectively recruited) or meets criteria for waiving of the requirement for consent (retrospectively recruited)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (5)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Austin Hospital Coordinator of this site? Confirm its status | Melbourne | Australia | Not yet recruiting |
| Peter MacCallum Cancer Centre Coordinator of this site? Confirm its status | Melbourne | Australia | Not yet recruiting |
| Calvary Mater Newcastle Hospital Coordinator of this site? Confirm its status | Waratah | Australia | Not yet recruiting |
| Westmead Hospital Coordinator of this site? Confirm its status | Westmead | Australia | Not yet recruiting |
| Princess Alexandra Hospital Coordinator of this site? Confirm its status | Woolloongabba | Australia | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.